

Zelira Therapeutics Ltd

14:35 27 Feb 2020

Emerald Clinics gets nod for Zelira's opioid sparing clinical trial

Emerald Clinics Ltd (ASX: EMD) has entered into a clinical trial research agreement to accelerate the completion of the Zelira sponsored trial at St Vincent's Hospital in Melbourne.

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) has now fully enrolled its Phase 1 Dose Escalation

Trial in patients on long-term opioid treatment.

The trial is called "A study to evaluate the safety, tolerability, and pharmacokinetics of a medicinal cannabinoid oil formulation in chronic non-cancer pain participants on long term opioid treatments."

No serious adverse events from dosing patients have been reported to date and dosing is expected to be completed by April 2020.

Zelira pleased to expand partnership with Emerald Clinics
Emerald Clinics' managing director and CEO Dr Michael Winlo said: "We are pleased to be working with Zelira, who are investing in the rigorous, product-specific clinical studies required to bring cannabinoid-based medical products into the mainstream where appropriate.

"Undertaking this trial validates our model of co-creating evidence with our patients while providing high-quality care.

"We are excited to be building upon the collaboration announced in 2019 and look forward to leveraging Real World Evidence (RWE) and traditional clinical trials to support Zelira's strategy and ultimately improve the health and wellbeing of our patients."

Zelda's managing director Dr Richard Hopkins said: "We're also pleased for the opportunity to expand our partnership with Emerald Clinics by bringing them on as a second site.

"We have been impressed by their ability to complement the efforts of the St Vincent team by rapidly screening and enrolling eligible patients into trial.

Trial could be first of its kind

"To our knowledge, this is the first clinical trial to be designed with a primary end-point assessing the efficacy of a full spectrum plant-derived cannabis formulation containing THC and CBD to reduce opioid dependence in chronic non-cancer patients.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

Price: 0.062

Market Cap: \$59.91 m

1 Year Share Price Graph



Share Information

Code: ZLD

Listing: ASX

52 week High Low
0.091 0.022

Sector: Cannabis

Website: www.zeldatherapeutics.com

Company Synopsis:

Zelira Therapeutics Ltd (ASX:ZLD) is a medicinal cannabis company focused on first-in-class human clinical trials for insomnia, autism and opioid reduction.

action@proactiveinvestors.com.au

investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).